$IOVA News

IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen

Iovance Biotherapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds

Iovance Biotherapeutics: Progress With Caveats

Iovance Biotherapeutics Says Therapeutic Goods Administration Of Australia Grants Approval With Conditions Of Amtagvi, Tumor-Derived Autologous T Cell Immunotherapy, For Previously Treated Advanced Melanoma

Iovance Biotherapeutics Announces Allowance To Proceed From FDA For Investigational New Drug Application For Phase 1/2 Basket Study Of IOV-5001

Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $14

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market

Iovance Biotherapeutics Sees FY2026 Sales $350.000M-$370.000M vs $370.477M Est

Iovance Biotherapeutics Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $71.430M Miss $78.396M Estimate

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?

Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA)

Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains?

Obsidian, Galera to advance cell therapy following reverse merger

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?

Iovance Biotherapeutics Option Alert: Fri $4 Calls Sweep (3) Near The Bid: 2008 @ $0.401 Vs 3647 OI; Earnings 5/7 After Close [Est] Ref=$4.04

Iovance Biotherapeutics Option Alert: Fri $4 Calls Sweep (3) Near The Bid: 2008 @ $0.401 Vs 3647 OI; Earnings 5/7 After Close [Est] Ref=$4.04

Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help